FindTrial
Sign In

Latanoprost (0.005%)

DRUG6 trials

Sponsors

Alcon Research, University of Maryland, Baltimore, Zagazig University, Lagos State Health Service Commission, Qlaris Bio, Inc.

Conditions

GlaucomaGlaucoma, Angle-ClosureOAG - Open-Angle GlaucomaOHT - Ocular HypertensionOcular HypertensionPrimary Open Angle Glaucoma or Ocular HypertensionSuspect GlaucomaTreatment Outcome

Early Phase 1

Optic Nerve Head Strain in Non-glaucoma Subjects
RecruitingNCT07425535
Johns Hopkins UniversityGlaucoma
Start: 2026-06-24End: 2028-03-31Target: 30Updated: 2026-07-13

Phase 1

Effect of Latanoprost on Optic Nerve Perfusion
CompletedNCT06629129
Zagazig UniversityTreatment Outcome
Start: 2024-06-24End: 2024-08-30Updated: 2024-10-08

Phase 2

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
CompletedNCT07354516
Qlaris Bio, Inc.OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Start: 2026-03-18End: 2026-07-22Updated: 2026-07-29

Phase 3

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
CompletedNCT00051181
Alcon ResearchGlaucoma, Angle-Closure, Ocular Hypertension
Start: 2000-01-31End: 2003-06-30Updated: 2008-08-05

Phase 4

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
RecruitingNCT04401982
University of Maryland, BaltimoreOcular Hypertension, Suspect Glaucoma
Start: 2026-07-02End: 2027-03-17Target: 50Updated: 2026-07-02

Unknown Phase

A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital
RecruitingNCT07310719
Lagos State Health Service CommissionPrimary Open Angle Glaucoma or Ocular Hypertension
Start: 2025-10-15End: 2026-11-30Target: 138Updated: 2025-12-30